Collaborate with the functional genomics screening laboratory

This funding opportunity enables UK-based academic groups and industry parties to collaborate with the Functional Genomics Screening Laboratory (FGSL) on projects using complex human in vitro models for CRISPR screening to better understand model biology and enable target identification. The FGSL is a joint venture between MRC, AstraZeneca, and the Milner Therapeutics Institute at the University of Cambridge, established as part of MRC's and BBSRC's functional genomics initiative. The service from the FGSL is already funded, with screens run by scientists employed at Milner Therapeutics Institute. Financial support for consumables is available either from AstraZeneca (where the model is of interest to AstraZeneca) or from a screening access fund provided by MRC. Applicants must be researchers eligible for MRC funding, though UK-based SMEs and industry parties may also be considered where space permits. This is an open opportunity with no closing date. Applications are reviewed by the Joint Steering Committee twice a year (May/June and November/December). The collaboration allows access to state-of-the-art arrayed functional genomics screening capabilities and CRISPR libraries provided through collaboration with AstraZeneca and MTI.